| Name | Title | Contact Details |
|---|
Lyons Lavey Nickel Swift is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Executive Health Exams International is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ohara LLC is a Sioux Falls, SD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The DHA is a joint, integrated Combat Support Agency that enables the Army, Navy, and Air Force medical services to provide a medically ready force and ready medical force to Combatant Commands in both peacetime and wartime. The DHA supports the delivery of integrated, affordable, and high quality health services to 9.5 million Military Health System beneficiaries and is responsible for driving greater integration of clinical and business processes across the MHS. The DHA oversees the delivery of health care services like the TRICARE Health Plan, pharmacy, public health, and health information technology. DHA carries out these operations using a global health care network of military and civilian medical professionals and more than 400 military hospitals and clinics. This network strengthens the delivery of health care to MHS beneficiaries by merging proven clinical and business practices and emphasizing the experience of the patient. Exciting changes are taking place as we are in the process of reorganizing how we manage the military`s medical centers, hospitals and clinics around the world, shifting administration and management responsibility for these facilities from the Army, Navy and Air Force to the Defense Health Agency. A single integrated system will support improvements to the readiness of our operational and medical forces to meet our missions around the world, while providing outstanding care to all of those who depend on us, on the battlefield and at home.
Voyager Therapeutics is developing life-changing gene therapies from discovery, preclinical and clinical development, through to commercialization. We focus on people living with severe neurological diseases that lack safe and effective treatment options, particularly in the areas of Parkinson`s disease, monogenic forms of amyotrophic lateral sclerosis (ALS), Friedreich`s ataxia, Huntington`s disease, Alzheimer`s Disease and other tau-related neurodegenerative diseases, and severe, chronic pain. We are also committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector engineering and optimization, dosing techniques, as well as process development and production. Our management team and founders represent some of the most esteemed scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference, neuroscience preclinical and clinical development, and manufacturing. We have broad strategic collaborations with Genzyme, a Sanofi company, AbbVie and the University of Massachusetts Medical School (UMMS). We have also entered into license and other agreements with UMMS, the University of California San Francisco and Stanford University to access relevant technology and data.